ClinicalTrials.gg
CompletedNCT00746681Updated Dec 21, 2009

Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive Bladder

A Phase 2 interventional study of Tolterodine & Pregabalin and Tolterodine in Overactive Bladder, sponsored by Pfizer. Completed at 23 sites in 6 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-12-21.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
188
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 30 studies testing tolterodine in Urinary Bladder, Overactive — 3 open to participants now, 3 under way, 1 of them phase 3. tolterodine · Urinary Bladder, Overactive.

Enrollment
10th of 29
188 · median 100
Started
2005
the only one that year
Phase 2
3 of 30
none open now
Registered
12th of 30
by date

Among the 30 studies testing tolterodine in Urinary Bladder, Overactive, this one is the 10th largest by enrollment of the 29 interventional ones that give a count, is the only one that started in 2005, is one of 3 in phase 2, and was the 12th registered.

Urinary Bladder, Overactive

860 studies on the registry are indexed under Urinary Bladder, Overactive; 128 are open to participants now.

Browse Urinary Bladder, Overactive studies →

Open to participants now

3 of the 30 studies testing tolterodine in Urinary Bladder, Overactive are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tolterodine

tolterodine: first FDA approval 1998 (DETROL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing tolterodine in Urinary Bladder, Overactive, or all of them as a file.
02

Study summary

Tolterodine is approved for use in the treatment of overactive bladder (OAB). The study is designed to a investigate whether pregabalin may have efficacy in OAB and whether the efficacy is altered when it is combined with tolterodine.

03

Conditions studied

  • Overactive Bladder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women > 18 years Old
  • Diagnosis of OAB (micturition frequency >/= 8 times per day; urinary urgency >/= 4 times per week)

Exclusion criteria

Exclusion Criteria:

  • Subjects with symptoms of overactive bladder for less than 6 months prior to randomization.
  • Significant stress incontinence as determined by the investigator e.g. stress predominant mixed incontinence, positive cough provocation test.
  • Subjects with any condition that would contraindicate the use of tolterodine or pregabalin, including: Uncontrolled narrow angle glaucoma; Urinary retention; Myasthenia gravis; Gastric retention; Severe ulcerative colitis; Toxic megacolon; Rare hereditary problems of galactose intolerance; Fructose intolerance; Sucrose-isomalate insufficiency; Lapp lactase deficiency; Glucose-galactose malabsorption.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
188 participants (actual)

Study arms

  • Experimental
    A

    Tolterodine SR 2 mg once daily combined with pregabalin 75 mg twice daily

    Drug: Tolterodine & Pregabalin

  • Active comparator
    B

    Tolterodine SR 4 mg once daily

    Drug: Tolterodine

  • Placebo comparator
    C

    Placebo

    Drug: Placebo

  • Experimental
    D

    Tolterodine SR 4 mg once daily combined with pregabalin 150 mg twice daily

    Drug: Tolterodine & Pregabalin

  • Experimental
    E

    Pregabalin 150 mg twice daily

    Drug: Pregabalin

Interventions

  • DrugTolterodine & Pregabalin

    Drug pages: Tolterodine · Pregabalin

    Tolterodine SR Oral, 2mg, once daily for 4 weeks Pregabalin, Oral, 75 mg, twice daily for 4 weeks

  • Tolterodine SR, Oral, 4 mg, once daily for 4 weeks

  • DrugPlacebo

    Placebo, Oral, twice daily for 4 weeks

  • DrugTolterodine & Pregabalin

    Drug pages: Tolterodine · Pregabalin

    Tolterodine SR Oral, 4mg, once daily for 4 weeks Pregabalin, Oral, 150 mg, twice daily for 4 weeks

  • Pregabalin, Oral, 150 mg twice daily for 4 weeks

06

What researchers measure

Primary outcomes

  1. Change in mean voided volume per micturition (from baseline).

    Time frame: 4 weeks

Secondary outcomes

  1. Percentage and absolute change in incontinence episode frequency after 4 weeks of treatment (for subjects with incontinence at baseline).

    Time frame: 4 Weeks

  2. Percentage and absolute change in urgency episode frequency

    Time frame: 4 Weeks

  3. Mean severity of urgency episodes

    Time frame: 4 Weeks

  4. Percentage and absolute change in micturition frequency

    Time frame: 4 Weeks

  5. Percentage and absolute change in normalized micturition frequency (NMF)

    Time frame: 4 Weeks

  6. Patient perception of their urinary urgency (using the OAB-q symptom severity scale)

    Time frame: 4 Weeks

  7. Patient perception of Health Related Quality of Life (using the OAB-q SF HRQL scale)

    Time frame: 4 Weeks

  8. Patient Perception of Bladder Condition (PPBC) scale

    Time frame: 4 Weeks

07

Study locations

23 sites
  • Pfizer Investigational Site
    Hradec Kralove, 500 05, Czech Republic
  • Pfizer Investigational Site
    Praha 1, 110 00, Czech Republic
  • Pfizer Investigational Site
    Praha 3, 130 00, Czech Republic
  • Pfizer Investigational Site
    Praha 4 - Krc, 140 59, Czech Republic
  • Pfizer Investigational Site
    Usti Nad Labem, 401 13, Czech Republic
  • Pfizer Investigational Site
    Kaunas, LT-47144, Lithuania
  • Pfizer Investigational Site
    Kaunas, LT-50009, Lithuania
  • Pfizer Investigational Site
    Vilnius, LT-01118, Lithuania
  • Pfizer Investigational Site
    Vilnius, LT-08661, Lithuania
  • Pfizer Investigational Site
    Haugesund, 5507, Norway
  • Pfizer Investigational Site
    Moelv, N-2390, Norway
  • Pfizer Investigational Site
    Trondheim, 7006, Norway
  • Pfizer Investigational Site
    Bratislava, 901 01, Slovakia
  • Pfizer Investigational Site
    Kosice, 040 11, Slovakia
  • Pfizer Investigational Site
    Martin, Slovakia
  • Pfizer Investigational Site
    Skalica, 909 82, Slovakia
  • Pfizer Investigational Site
    Lulea, 97180, Sweden
  • Pfizer Investigational Site
    Norrkoping, 601 82, Sweden
  • Pfizer Investigational Site
    Stockholm, 141 86, Sweden
  • Pfizer Investigational Site
    Dundee, Tayside DD1 9SY, United Kingdom
  • Pfizer Investigational Site
    Bristol, BS10 5NB, United Kingdom
  • Pfizer Investigational Site
    Dundee, DD1 9SY, United Kingdom
  • Pfizer Investigational Site
    Plymouth, PL6 8DH, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005 and a completion of Nov 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2008
First posted
Sep 4, 2008
Start
Dec 2005
CompletionActual
Nov 2006
Last update
Dec 21, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00746681
Lead sponsor
Pfizer
First posted
Sep 4, 2008
Start date
Dec 2005
Completion
Nov 2006
Last update
Dec 21, 2009

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tolterodine · Pregabalin

Start the discussion